

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong under the Companies Ordinance)*

**(Stock code: 1093)**

### **INSIDE INFORMATION PROPOSED SPIN-OFF AND LISTING OF CSPC XNW ON A STOCK EXCHANGE IN THE PRC**

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company is considering a possible spin-off and separate listing of CSPC XNW Pharmaceutical Joint Stock Company Limited\* (石藥集團新諾威製藥股份有限公司) (“**CSPC XNW**”) and its subsidiaries on a stock exchange in the People’s Republic of China (“**PRC**”) (the “**Proposed Spin-off and Listing**”). CSPC XNW is an indirect non-wholly-owned subsidiary of the Company and currently mainly engages in the manufacture and sales of caffeine (food additives and bulk drugs) and vitamin C health supplement and beverage products.

On 17 April 2017, the financial advisor of CSPC XNW received a written acknowledgement from the Hebei Regulatory Bureau of China Securities Regulatory Commission that the application for pre-listing tutoring process in connection with the Proposed Spin-off and Listing has been filed and registered.

The Company will submit an application in relation to the Proposed Spin-off and Listing to the Hong Kong Stock Exchange for approval pursuant to Practice Note 15 of the Listing Rules in due course.

\* *For identification purpose only*

The Proposed Spin-off and Listing, if materialised, will constitute a deemed disposal under Chapter 14 of the Listing Rules. The Company will make further disclosure as and when appropriate pursuant to the relevant requirements of the Listing Rules.

**Shareholders of the Company and potential investors should note that, the Proposed Spin-off and Listing is subject to, inter alia, the prevailing market conditions and approvals from relevant authorities, including the China Securities Regulatory Commission, the relevant stock exchange in the PRC and the Hong Kong Stock Exchange. Accordingly, shareholders of the Company and potential investors should be aware that, the Company does not guarantee that the Proposed Spin-off and Listing will proceed nor the timing thereof. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dongchen**  
*Chairman*

Hong Kong, 18 April 2017

*As at the date of this announcement, the board of directors of the Company comprises Mr. CAI Dongchen, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. Wang Jinxu, Mr. WANG Zhenguo, Mr. LU Hua, Mr. WANG Shunlong and Mr. Chak Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*